Splicing variants of versican in CD133+/CD44+ prostate cancer stem cells
| dc.authorid | 0000-0003-1580-8371 | |
| dc.authorid | 0000-0002-7059-1884 | |
| dc.contributor.author | Ayla, Şule | |
| dc.contributor.author | Karakoç, Emre | |
| dc.contributor.author | Yozgat Byrne, Yasemin | |
| dc.contributor.author | Parlayan, Cüneyd | |
| dc.contributor.author | Keskin, İlknur | |
| dc.contributor.author | Karahüseyinoğlu, Serçin | |
| dc.contributor.author | Taşkıran, Ayşegül | |
| dc.contributor.author | Öktem, Gülperi | |
| dc.date.accessioned | 2024-07-11T06:11:53Z | |
| dc.date.available | 2024-07-11T06:11:53Z | |
| dc.date.issued | 2024 | |
| dc.department | İstanbul Medipol Üniversitesi, Rektörlük, Sağlık Bilim ve Teknolojileri Araştırma Enstitüsü | |
| dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Histoloji ve Embriyoloji Ana Bilim Dalı | |
| dc.description.abstract | A cancer mass is composed of a heterogeneous group of cells, a small part of which constitutes the cancer stem cells since they are less differentiated and have a high capacity to develop cancer. Versican is an extracellular matrix protein located in many human tissues. The mRNA of versican has been shown to have “splicing patterns” as detected by RT-PCR, northern blot analysis, and cDNA sequencing. Based on this knowledge this study aims to reveal the splice variants of versican molecules, which are thought to be involved in the pathogenesis of the DU-145 human prostatic carcinoma cell line and prostatic cancer stem cells isolated from this cell line. In this study, RWPE-1 normal prostatic and DU-145 human prostate cancer cell lines have been used. Prostatic cancer stem cells and the remaining group of non-prostatic-cancer stem cells (bulk population) were isolated according to their CD133+/CD44+. RNA was isolated in all groups, and sequence analysis was accomplished for splicing variants by Illumina NextSeq 500 sequencing system. The results were analyzed by bioinformatic evaluation. As five isoforms of the versican gene in the differential transcript expression are analyzed, it was observed that a significant change was only found in the isoforms Versican 0 and Versican 1. In this study, we explored the function of this molecule which we think to be effective in cancer progression, and suggested that more valuable results can be obtained after the accomplishment of in vivo experiments. | |
| dc.identifier.citation | Ayla, Ş., Karakoç, E., Yozgat Byrne, Y., Parlayan, C., Keskin, İ., Karahüseyinoğlu, S. ... Öktem, G. (2024). Splicing variants of versican in CD133+/CD44+ prostate cancer stem cells. Pathology Research and Practice, 260. http://dx.doi.org/10.1016/j.prp.2024.155440 | |
| dc.identifier.doi | 10.1016/j.prp.2024.155440 | |
| dc.identifier.issn | 0344-0338 | |
| dc.identifier.issn | 1618-0631 | |
| dc.identifier.pmid | 38964119 | |
| dc.identifier.scopus | 2-s2.0-85197408368 | |
| dc.identifier.scopusquality | Q2 | |
| dc.identifier.uri | http://dx.doi.org/10.1016/j.prp.2024.155440 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12511/12710 | |
| dc.identifier.volume | 260 | |
| dc.identifier.wos | 001265418700001 | en_US |
| dc.identifier.wosquality | Q2 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.institutionauthor | Yozgat Byrne, Yasemin | |
| dc.institutionauthor | Keskin, İlknur | |
| dc.language.iso | en | |
| dc.relation.ispartof | Pathology Research and Practice | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Adhesion Molecule | |
| dc.subject | Cancer Stem Cell | |
| dc.subject | Prostate Cancer | |
| dc.subject | Versican | |
| dc.title | Splicing variants of versican in CD133+/CD44+ prostate cancer stem cells | |
| dc.type | Article |
